Eltrombopag is relatively new drug used in Thrombocytopenia. Its dose should be adjusted based on platelets count. It should be stopped when platelets count reach 400,000/mm³. Here, we share our case report of stopping Eltrombopag based on platelets increment in secondary reactive thrombocytosis irrespective of Eltrombopag treatment.

Polycythemia vera (PV) characterize by an increase in RBCs and hemoglobin concentration. The typical presentation of PV is a plethora and thrombosis. Sites of thrombosis are Lower limbs. Rare sites of thrombosis are sagittal sinus. We report a case of 52 years old women with polycythemia complicated with sagittal thrombosis